Radioimmunodetection of cancer of gastrointestinal tract and liver metastasis with I-131 anti-CEA and I-131 anti-CA19-9 monoclonal antibody cocktail (IMACIS-1)

1994 ◽  
Vol 8 (3) ◽  
pp. 163-169 ◽  
Author(s):  
Yukihiko Naruki ◽  
Yoshihisa Urita ◽  
Yukitaka Miyachi ◽  
Sachio Otsuka ◽  
Masahiro Noguchi ◽  
...  
2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Takuhisa Okada ◽  
Yasumitsu Hirano ◽  
Shintaro Ishikawa ◽  
Hiroka Kondo ◽  
Toshimasa Ishii ◽  
...  

Abstract Background Clear cell sarcoma-like tumor of the gastrointestinal tract (CCSLTGT) is extremely rare. It is a mesenchymal neoplasm that usually forms in the small intestine of adolescents and young adults, is prone to local recurrence and metastasis, and has a high mortality rate. We report a patient with CCSLTGT with lymph node- and liver metastases, who continues to survive 6 years after initial surgical resection. Case presentation A 38-year-old woman presented with lightheadedness. Laboratory analysis revealed anemia (hemoglobin, 6.7 g/dL), and enhanced computed tomography (CT) demonstrated a mass in the small intestine, about 6 cm in diameter, with swelling of 2 regional lymph nodes. Double-balloon small intestine endoscopic examination revealed a tumor accompanied by an ulcer; the biopsy findings suggested a primary cancer of the small intestine. She was admitted, and we then performed a laparotomy for partial resection of the small intestine with lymph node dissection. Pathologic examination revealed CCSLTGT with regional lymph node metastases. About 3 years later, follow-up CT revealed a single liver metastasis. Consequently, she underwent a laparoscopic partial liver resection. Histopathologic examination confirmed that the liver metastasis was consistent with CCSLTGT. It has now been 3 years without a recurrence. Conclusion Repeated radical surgical resection with close follow-up may be the only way to achieve long-term survival in patients with CCLSTGT.


2019 ◽  
Vol 16 (4) ◽  
pp. 793-807 ◽  
Author(s):  
Yinghui Rong ◽  
Fernando J. Torres-Velez ◽  
Dylan Ehrbar ◽  
Jennifer Doering ◽  
Renjie Song ◽  
...  

Author(s):  
Kevinkumar Kansagra ◽  
Deven Parmar ◽  
Sanjeev Kumar Mendiratta ◽  
Jatin Patel ◽  
Shuchi Joshi ◽  
...  

Abstract Background Limited supply, cost and potential for severe adverse effects observed with the blood derived rabies immunoglobulin products has led to search for alternative therapies. This issue has been addressed by developing an anti-rabies monoclonal antibody cocktail. Methods This is a phase 3, randomized, open-label, noninferiority trial conducted in patients with World Health Organization (WHO) category III exposure with suspected rabid animal. Eligible patients were assigned to either the test arm, TwinrabTM (docaravimab and miromavimab) or the reference arm, human rabies immunoglobulin (HRIG; Imogam® Rabies-HT), in a ratio of 1:1. The primary endpoint was the comparison of responder rates between the 2 arms assessed as percentage of those with rabies virus neutralizing antibodies titers ≥0.5 IU/mL on day 14. Results A total of 308 patients were equally randomized into the 2 arms. In the per-protocol (PP) population, there were 90.21% responders in the TwinrabTM arm and 94.37% in the HRIG arm. The geometric mean of rapid fluorescent foci inhibition test titers in the PP on day 14 were 4.38 and 4.85 IU/mL, for the TwinrabTM and HRIG arms, respectively. There were no deaths or serious adverse events reported. Conclusions This study confirmed that TwinrabTM is noninferior to HRIG in terms of providing an unbroken window of protection up to day 84. This trial in healthy adults with WHO category III exposure from suspected rabid animal also establishes the safety of TwinrabTM in patients with 1 WHO approved vaccine regimen (Essen). Clinical Trials Registration CTRI/2017/07/009038.


2007 ◽  
Vol 58 (1) ◽  
pp. 359-368 ◽  
Author(s):  
John de Kruif ◽  
Alexander B.H. Bakker ◽  
Wilfred E. Marissen ◽  
R. Arjen Kramer ◽  
Mark Throsby ◽  
...  

1993 ◽  
Vol 46 (4) ◽  
pp. 323-329 ◽  
Author(s):  
J D Milton ◽  
D Eccleston ◽  
N Parker ◽  
A Raouf ◽  
C Cubbin ◽  
...  

2017 ◽  
Vol 5 (5) ◽  
pp. 417-424 ◽  
Author(s):  
Paul C. Tumeh ◽  
Matthew D. Hellmann ◽  
Omid Hamid ◽  
Katy K. Tsai ◽  
Kimberly L. Loo ◽  
...  

Toxins ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 215 ◽  
Author(s):  
Yinghui Rong ◽  
Michael Pauly ◽  
Adrian Guthals ◽  
Henry Pham ◽  
Dylan Ehrbar ◽  
...  

PB10 IgG1, a monoclonal antibody (MAb) directed against an immunodominant epitope on the enzymatic subunit (RTA) of ricin toxin (RT), has been shown to passively protect mice and non-human primates from an aerosolized lethal-dose RT challenge. However, it was recently demonstrated that the therapeutic efficacy of PB10 IgG1 is significantly improved when co-administered with a second MAb, SylH3, targeting RT’s binding subunit (RTB). Here we report that the PB10/SylH3 cocktail is also superior to PB10 alone when used as a pre-exposure prophylactic (PrEP) in a mouse model of intranasal RT challenge. The benefit of the PB10/SylH3 cocktail prompted us to engineer a humanized IgG1 version of SylH3 (huSylH3). The huPB10/huSylH3 cocktail proved highly efficacious in the mouse model, thereby opening the door to future testing in non-human primates.


Author(s):  
Thomas Müller ◽  
Bernhard Dietzschold ◽  
Hildegund Ertl ◽  
Anthony R. Fooks ◽  
Conrad Freuling ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document